November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected ...
In the Society for Cardiovascular Angiography and Interventions’ (SCAI) comment letter to the Centers for Medicare& Medicaid Services (CMS) regarding the 2018 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule, SCAI took the opportunity to ask CMS to add the acute myocardial infarction percutaneous coronary intervention (AMI-PCI) Current Procedural Terminology (CPT) code (92941) to the inpatient-only (IPO) list.
November 9, 2017 — 4C Medical Technologies Inc. announced that its medical device for mitral regurgitation (MR) was ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience ...
A discussion with William W. O’Neill, M.D., medical director, Center for Structural Heart Disease, Henry Ford Hospital ...
November 8, 2017 — Physicians at UnityPoint Health Methodist, Peoria, Ill., are now offering fast, safe and accurate ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the ...
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on ...
November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Investigators in the FAVOR II China and FAVOR II Europe-Japan studies recently presented their results at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, Oct. 29-Nov. 2 in Denver.
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe, symptomatic, aortic stenosis patients. Outcomes from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial and the Evolut R FORWARD “real-world” study were presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, Oct. 29-Nov. 2 in Denver, reinforcing the valve’s strong performance in healthier, more active patients.
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the ...
A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyterian ...
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and can ...